In horses after colic surgery, do erythromycin or metoclopramide infusions vs standard care reduce postoperative ileus? (Shelf scope: the non-lidocaine prokinetic class — lidocaine evidence homes on Shelves #179 and #835.)
Shelf #797 · gate-verified and displayed under the developer's blinded-trial rule
POSSIBLE: For the non-lidocaine prokinetic class, the clinical evidence rests on one randomised blind trial, and it is positive but unquantified in its record. In van der Velden 1993 (PMID: 8122356; 70 horses surgically treated for colic caused by disorders of the small intestine, in a randomized blind trial), cisapride 0.1 mg/kg intramuscularly at 8-hour intervals appeared to reduce the incidence of post-operative ileus, accelerated the restoration of bowel motility and reduced the period of post-operative intensive care; the abstract reports no group rates, no group sizes per arm and no P values, so the size of the effect cannot be stated, and what the control group received is not described in the record. The only clinical-outcome dataset for the class as actually used, Smith 2005 (PMID: 15908242; 55 horses with post-operative ileus following pedunculated lipoma obstruction at two hospitals, treated with four prokinetic agents), found prokinetic use was NOT associated with short-term survival in multivariable models (P = 0.15), in an analysis the authors themselves show was underpowered and describe as suggestive of limited efficacy — a null on survival in a retrospective dataset, not a test of ileus resolution. For the two drugs named in the mined question, erythromycin and metoclopramide, no clinical trial in horses with post-operative ileus was found at drafting: their equine evidence is motility surrogates in healthy or experimental animals (erythromycin increased ileal and pelvic-flexure myoelectric activity after electrode-implantation surgery in 8 healthy horses, Roussel 2000, PMID: 10772107; metoclopramide and cisapride improved jejunal motility indices against a water control in 7 healthy Thoroughbreds, Okamura 2009, PMID: 18723200), which cannot carry a clinical ileus claim. Design class (a): randomisation and blinding are established by the carded van der Velden 1993 record (record wording 'randomized blind trial'; MeSH includes Double-Blind Method; indexed as a Randomized Controlled Trial) answering this shelf's own comparison — a non-lidocaine prokinetic versus control in horses after colic surgery. The stamp is POSSIBLE, not LIKELY, because that trial is single, from 1993, and reports no figures in its record, the only other clinical dataset is a null retrospective survival analysis, and erythromycin/metoclopramide specifically have no clinical-outcome evidence. Boundary: intravenous lidocaine evidence is NOT re-carded here — it homes on Shelf #179 (IV lidocaine CRI for post-operative ileus) and Shelf #835 (intraoperative lidocaine); the one carded record whose dataset includes lidocaine-treated horses (Smith 2005) is carded for its prokinetic-class analysis, in which the agents were not separated, and that limitation is disclosed on its card. Drafted Nov 10, 2026 (VetMed build, topic #797); all figures from the abstracts fetched and verified at drafting.
Randomized blind clinical trial (record's own wording; publication types: Clinical Trial, Journal Article, Randomized Controlled Trial; MeSH includes Double-Blind Method)
Who: Horses: 70 horses surgically treated for colic caused by disorders of the small intestine, included in a randomized blind trial of cisapride (0.1 mg/kg bodyweight intramuscularly at 8-hour intervals) for the post-operative restoration of gut motility. The record does not state the per-arm group sizes or describe the control treatment in the abstract.
Result: On the record's own wording: cisapride appeared to reduce the incidence of post-operative ileus; it accelerated the restoration of bowel motility, reducing the period of post-operative intensive care; and the authors conclude that cisapride is an effective and useful drug in the post-operative treatment of horses after surgery of the small intestine. The abstract gives no percentages, no event counts, no P values and no adverse-effect data, so no effect size can be quoted from this record.
Watch out: NO FIGURES IN THE RECORD: the positive result is qualitative in the abstract — anyone needing an effect size must go to the full text, and this card deliberately quotes none. The trial is from 1993, covers small-intestinal colic surgery only (not large-colon or other lesions), and the abstract does not say what the comparison group received. Cisapride's availability is restricted in many jurisdictions, which limits how directly a 1993 result can be applied, but the record itself makes no availability claim and none is carded.
van der Velden MA, Klein WR. The effects of cisapride on the restoration of gut motility after surgery of the small intestine in horses; a clinical trial. Vet Q. 1993;15(4):175-9. PMID: 8122356. Registry ID: none in the record. MeSH: Animals · Cisapride · Colic/surgery/veterinary* · Double-Blind Method · Female · Gastrointestinal Motility/drug effects*/physiology · Horse Diseases/surgery* · Horses · Intestinal Diseases/surgery/veterinary* · Intestine, Small/surgery* · Male · Piperidines/administration & dosage/pharmacology* · Serotonin Antagonists/administration & dosage/pharmacology*
Retrospective evaluation study (publication types: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Who: Horses: 55 horses with post-operative ileus (POI) following pedunculated lipoma obstruction (PLO), combined from two hospitals. Prokinetic treatment in the dataset covered four agents; the record's MeSH names cisapride, erythromycin, metoclopramide and lidocaine, and the agents were analysed together as prokinetic use, not separately.
Result: With death as the outcome in multivariable models, breed and hospital were significantly associated with outcome but the use of prokinetic agents was not (P = 0.15). The authors' sample-size estimates indicate the low power of the study to detect differences in outcome; they state that it was not possible definitively to evaluate the efficacy of prokinetics as treatment for POI following PLO using retrospective data, that the data were suggestive of limited efficacy of prokinetics, and that the hospital association likely reflects differences in clinician decision making. They call for prospective randomised clinical trials.
Watch out: CLASS-LEVEL, NOT DRUG-LEVEL: lidocaine was one of the four agents in this dataset and the analysis does not separate agents, so this card speaks to prokinetics as used in practice, not to any single non-lidocaine drug — and it does not re-card any Shelf #179/#835 lidocaine record. The outcome is short-term survival (death), not ileus duration or reflux; a retrospective, two-hospital dataset with confounding by indication (sicker horses are more likely to be given prokinetics) and, by the authors' own calculation, low power. A single lesion type (pedunculated lipoma obstruction) limits the scope.
Smith MA, Edwards GB, Dallap BL, Cripps PJ, Proudman CJ. Evaluation of the clinical efficacy of prokinetic drugs in the management of post-operative ileus: can retrospective data help us? Vet J. 2005;170(2):230-6. PMID: 15908242. Registry ID: none in the record. MeSH: Animals · Cisapride/therapeutic use · Digestive System Surgical Procedures/adverse effects* · Erythromycin/therapeutic use · Gastrointestinal Agents/therapeutic use* · Horse Diseases/drug therapy*/etiology · Horses · Ileus/complications/drug therapy/etiology/veterinary* · Lidocaine/therapeutic use · Metoclopramide/therapeutic use · Retrospective Studies · Risk Factors
Synthesis
Who: Synthesis of the two cards above (van der Velden 1993, 70 colic-surgery horses, cisapride; Smith 2005, 55 horses with POI after lipoma obstruction, prokinetic class) and of the near-miss records documented in the result, which were fetched at drafting and deliberately not carded as claim-carriers.
Result: (1) Cisapride beyond the trial: Gerring & King 1989 (PMID: 9118107) found cisapride and domperidone both effective in restoring electrical and mechanical activity, coordination of gastric and small-intestinal activity cycles and stomach-to-anus transit time in 3 ponies in which post-operative ileus was induced experimentally, and report that cisapride (0.1 mg/kg intramuscularly, three to eight doses) prevented idiopathic post-operative ileus in 22 clinical colic-surgery cases — but the clinical part has no control group in the record, so it supports, and cannot extend, the randomised trial. (2) Erythromycin: Roussel 2000 (PMID: 10772107), in 8 healthy adult horses with implanted electrodes, found erythromycin 0.5 mg/kg increased myoelectric activity in the ileum during all post-operative recording sessions and in the pelvic flexure during all recording sessions, with some periods of significantly decreased activity, and the authors caution against extrapolating prokinetic studies in healthy animals to animals with abnormal gastrointestinal motility — a surrogate outcome in non-colic horses, not a clinical ileus trial. (3) Metoclopramide: Okamura 2009 (PMID: 18723200), in 7 healthy Thoroughbreds, found oral mosapride (1.0 and 2.0 mg/kg) facilitated gastric emptying, and jejunal motility improved after mosapride, metoclopramide (0.2 mg/kg) and cisapride (1.0 mg/kg) against a distilled-water control on electrointestinography — again healthy horses and motility indices, not post-operative ileus outcomes; that study's lidocaine arm is not used here (lidocaine homes on Shelves #179/#835). (4) Prokinetic-use surveys (e.g. PMID: 15104636, a survey of prokinetic use in horses with gastrointestinal injury) document practice, not efficacy, and were not carded. Bottom line: the class claim rests on cisapride's single randomised blind trial; for erythromycin or metoclopramide infusions specifically, there is no clinical-outcome evidence in horses with post-operative ileus, and this shelf does not pretend otherwise.
Watch out: One-home check at drafting: none of PMIDs 8122356, 15908242, 9118107, 10772107, 18723200 or 15104636 appears in any other pack on disk, and no Shelf #179 or Shelf #835 claim-carrier (PMIDs 12465774, 16409411, 19422470, 27459996, 15515986, 18321812, 24986751) is re-carded here. The deliberate gap: if the only eligible records for a future update are lidocaine records, they belong on #179/#835, not on this shelf.
Synthesis of van der Velden MA & Klein WR. PMID: 8122356; Smith MA et al. PMID: 15908242; Gerring EL & King JN. PMID: 9118107; Roussel AJ et al. PMID: 10772107; Okamura K et al. PMID: 18723200; Van Hoogmoed LM et al. (survey) PMID: 15104636. Registry IDs as on the individual cards (none in the records).
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.